TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb

TuHURA Biosciences, Inc./NV

2025-Q2 EPS reported -$0.36

Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.
Initiated Phase 3 accelerated approval trial of IFx-2.0 with Keytruda in MCC under FDA SPA.
Raised $12.5M equity financing plus $3.0M from warrant exercise in June 2025; shares outstanding ~49.9M.
R&D expenses $4.9M (Q2 2025) vs $2.8M (Q2 2024); operating cash outflow ($10.9M) for 6 months.
Added to Russell 3000/2000 indices in June 2025; targets Phase 3 topline results 2H 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.